Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Immunosuppression: early-phase trial registry
5 of 13 indexed Immunosuppression trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 5 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Immunosuppression: 13 US clinical trials tracked, 5 recruiting.
Immunosuppression is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 3 of these trials.
Enrollment posture brief
Registry condition immunosuppression
OPEN 5 | RECR 38% | LATE 1 | EARLY 3 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Immunosuppression lists 5 open slots (38% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Immunosuppression on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Immunosuppression is recruiting below its size-band peers.
5 of 13 indexed trials (38.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Immunosuppression research.
National Eye Institute (NEI) accounts for 3 of 13 trials (23.1%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Immunosuppression trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
Immunosuppression splits between interventional and observational designs.
7 interventional and 6 observational studies make up this index (53.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
National Institute of Dental and Craniofacial Research (NIDCR)
NCT01568697
Pathological Myeloid Activation After Sepsis and Trauma
University of Florida
NCT05616130
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
University of California, Davis
NCT05060991
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
Linda Cendales
NCT02310867
Vascularized Composite Bladder Allograft Transplantation
University of Southern California
NCT05462561
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
National Eye Institute (NEI)
NCT00116090
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01638559
Immune Indicators of Uveitis
National Eye Institute (NEI)
NCT00089739
HLA-Identical Sibling Renal Transplant Tolerance
Northwestern University
NCT00619528
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
Northwestern University
NCT01678937
Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers
National Heart, Lung, and Blood Institute (NHLBI)
NCT01281995
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
National Eye Institute (NEI)
NCT00130637
Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment
Swedish Medical Center
NCT00714480
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Immunosuppression records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Immunosuppression trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Immunosuppression page
13 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Immunosuppression trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Immunosuppression trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immunosuppression condition card totals 13 registered trials; most-linked intervention Immunosuppression withdrawal; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.